<DOC>
	<DOCNO>NCT03094845</DOCNO>
	<brief_summary>hdmASIT+TM product base highly purified allergen fragment house dust mite . The purpose study assess safety clinical tolerability subcutaneous immunotherapy hdmASIT+TM patient house dust mite-induced allergic rhinoconjunctivitis compare placebo .</brief_summary>
	<brief_title>Safety Clinical Tolerability hdmASIT+TM Peptides Administered HDM-induced Allergic Patients</brief_title>
	<detailed_description />
	<criteria>A medical history moderate severe allergic rhinoconjunctivitis house dust mite least 12 month ( definition allergy severity accord ARIA ( Bousquet et al. , 2001 ) ) A positive skin prick test house dust mite Dermatophagoides pteronyssinus Specific IgE house dust mite Dermatophagoides pteronyssinus ≥ 0.7 kU/L Positive response Conjunctival Provocation Test ( CPT ) Being treat antiallergic medication least 12 month prior enrollment For asthmatic patient : confirm diagnosis control asthma accord Global Initiative Asthma ( GINA ) guideline ( step 13 , GINA 2014 ) , FEV1 ≥ 80 % patient 's reference value Previous immunotherapy house dust mite allergen within last 5 year Ongoing immunotherapy house dust mite allergens allergens History severe systemic reaction and/or anaphylaxis , include food ( e.g . peanut , marine animal ) Hymenoptera venom ( e.g . bee , wasp sting ) medication ( e.g . penicillin ) , etc . Partly control uncontrolled asthma accord GINA guideline ( GINA 2014 ) Chronic asthma emphysema , particularly forced expiratory volume 1 second ( FEV1 ) &lt; 80 % patient 's reference value ( ECSC ) History respiratory tract infection and/or exacerbation asthma within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>